medigraphic.com
ISSN 1561-3054 (Electronic)

2020, Number 3

<< Back Next >>

Rev Cubana Med Trop 2020; 72 (3)

Interleukin-10 gene polymorphisms and sustained virological response in Cuban patients coinfected with hepatitis C virus and human immunodeficiency virus

Montalvo VMC, Córdova GM, Rodríguez-Lay LÁ, Martínez MY, López HD, Valdés AL, Bello CM

Language: Spanish
References: 29
Page: 1-15
PDF size: 313.29 Kb.


ABSTRACT

Introduction: The study of patients infected with hepatitis C virus revealed that polymorphisms of a single nucleotide of the interleukin-10 (IL10) gene influence the sustained virological response to the treatment with interferon and ribavirin, and the immunopathogenesis of the disease.
Objective: Determine the frequency of single-nucleotide polymorphisms from the interleukin-10 gene promoter region according to the sustained virological response and the degree of liver injury.
Methods: A descriptive cross-sectional study was conducted and hepatitis C viral load was determined by RT-PCR. A sample of 25 Cuban HIV/HCV coinfected patients were studied 24 weeks after treatment with interferon and ribavirin. To evaluate the genetic variability of interleukin 10, the single-nucleotide polymorphisms were identified by nucleotide sequencing, -592 (A>C) and -819 (T>C). The degree of liver fibrosis was estimated by the aspartate aminotransferase / platelet index.
Results: Of the patients studied, 44.0% (11/25) achieved a sustained virological response and 56.0% (14/25) did not. In individuals displaying the response, a predominance was found of low interleukin-10 producing genotypes, -592AA (36.3% vs. 21.4%) and -819TT (54.5% vs. 21.4%). In those cases, allele frequency analysis showed a greater allele T frequency for SNP -819 (p= 0.0470). The aspartate aminotransferase / platelet index was compatible with kidney fibrosis without cirrhosis in patients without a sustained virological response, and indicated an absence of liver injury in coinfected patients displaying a response.
Conclusions: Results suggest that the variants evaluated of single-nucleotide polymorphisms of the interleukin-10 gene could be related to the sustained virological response and the pathogenesis of hepatitis C in the patients studied.


REFERENCES

  1. 1 . World Health Organization. HIV and hepatitis coinfections. 2019. [access: 03/01/2020]. Available from: Available from: https://www.who.int/hiv/topics/hepatitis/hepatitisinfo/en/

  2. Lo Re V, Kostman JR, Amorosa VK. Management Complexities of HIV/HCV Coinfection in the Twenty-First Century. Clin Liver Dis. 2008;12(3):587-ix. DOI: 10.1016/j.cld.2008.03.009

  3. 3 . European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C. J Hepatol. 2018;69:461-511. DOI: 10.1016/j.jhep.2018.03.026

  4. Govea M, Rivas A, Rodriguez R, Lozano SA, Aguilar CN, Zugasti A, et al. Gallic acid decreases hepatitis C virus expression through its antioxidant capacity. Exp Ther Med. 2016;11: 619-24. DOI: 10.3892/etm.2015.2923

  5. Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. Visc Med. 2019;35(3):161-70. DOI: 10.1159/000500963

  6. Smolders E, Thammajaruk N, de Kanter C, Colbers A, Chaiyahong P, Cuprasitrut T, et al. Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: Efficacy, safety and pharmacokinetics. Trop Med Int Health. 2018;23(3):295-305. DOI: 10.1111/tmi.13027

  7. 7 . Bello Corredor M, Rodriguez Lay L de A, Gutierrez Moreno A, Sariego Frometa S, Montalvo Villalba MC, Sanchez Sol A. Detection of hepatitis B and hepatitis C markers in HIV positive patients, 2000-2004. Rev Cubana Med Trop. 2005 [acceso: 03/01/2020];57(3):212-3. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375-07602005000300009

  8. Rodriguez Lay LL, Villalba MC, Corredor MB, Frometa SS, Hernandez JM, Carrera SD. HCV genotype determination in monoinfected and HIV co-infected patients in Cuba. Trans R Soc Trop Med Hyg. 2012;106(12):711-17. DOI: 10.1016/j.trstmh.2012.08.001

  9. Yan Z, Wang Y. Viral and host factors associated with outcomes of hepatitis C virus infection (Review). Mol Med Report. 2017;15:2909-24. DOI: 10.3892/mmr.2017.6351

  10. El-Karaksy HM, Sharaf SA, Mandour IA, Mogahed EA, Rady NH, El-Mougy FA. Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection. Hum Immunol. 2016;77(12):1248-53. DOI: 10.1016/j.humimm.2016.09.005

  11. Saxena M, Agrawal CC, Bid HK, Banerjee M. An interleukin-10 gene promoter polymorphism (-592A/C) associated with type 2 diabetes: a North Indian study. Bioch Genetics. 2012;50(7-8):549-59. DOI: 10.1007/s10528-012-9499-z

  12. Garcia M, Ochoa R, Lazo E, Valdivia I, Martínez L, Trujillo J, et al. Detección de anticuerpos contra el virus de la Hepatitis C en muestras de sangre colectadas en papel de filtro. Biotecnología Aplicada. 1995 [acceso: 03/01/2020];12(2):99-100. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252017000400002

  13. Bhattacharya DAM, Ansari IH, Striker R, Rehrauer WM. Naturally occurring genotype 2b/1a hepatitis C virus in the United States. Virology. 2011;8(458):1-8. DOI: 10.1186/1743-422X-8-458

  14. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Molecular Biology and Evolution. 2016;33:1870-1874. DOI: 10.1093/molbev/msw054

  15. Yang Y, Fa X. Role of IL-10 gene polymorphisms on the susceptibility for esophageal cancer and its association with environmental factors. Int J Clin Exp Pathol. 2015;8(8):9580-85. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583954

  16. Wai CT1, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. Aug 2003;38(2):518-26. DOI: 10.1053/jhep.2003.50346

  17. Hernández-Rodríguez WA, Trejo-Medinilla FM. Estudio genético poblacional de Frecuencias Alélicas para 15 marcadores STR presentes en la población del Estado de Zacatecas Aplicado a la Práctica Forense. Archivos Medicina. 2014;10(1:1):2-24. DOI: 10.3823/1209

  18. 18 . Aleman-Campos Y, Kouri-Cordella V, Perez-Santos L, Fonseca-Gomez C, Perez-Avila J, Ortega-Gonzalez LM, et al. HIV-1 Antiretroviral Resistance in Cuba, 2009-2014. MEDICC Rev. 2018 [acceso: 03/01/2020];20(3):15-21. Disponible en: Disponible en: https://www.scielosp.org/pdf/medicc/2018.v20n3/15-21

  19. Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc. 2019;22(Suppl 6):e25348. DOI: 10.1002/jia2.25348

  20. Kovari H, Russmann S, Ledergerber B, Muller D, Rotger M, Velli P, et al. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. PLoS One. 2015;10(7):e0133879. DOI: 10.1371/journal.pone.0134839

  21. Rossi C, Butt Z, Wong S, Buxton J, Islam N, Yu A, et al. Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in a Large Population-Based Cohort. J Hepatol. Nov 2018;69(5):1007-14. DOI: 10.1016/j.jhep.2018.07.025

  22. Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Chang KC, et al. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. J Gastroenterol Hepatol. 2012;27(6):1106-11. DOI: 10.1111/j.1440-1746.2011.06946.x

  23. Lazarus R, Klimecki WT, Palmer LJ, Kwiatkowski DJ, Silverman EK, Brown A, et al. Single-nucleotide polymorphisms in the interleukin-10 gene: differences in frequencies, linkage disequilibrium patterns, and haplotypes in three United States ethnic groups. Genomics. 2002;80(2):223-28. DOI: 10.1006/geno.2002.6820

  24. Naeemi H, Aslam R, Raza SM, Shahzad MA, Naz S, Manzoor S, et al. Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients. Arch Virol. 2018;163(4):997-1008. DOI: 10.1007/s00705-018-3711-3

  25. Owen JA, Punt J, Stranford SA. Kuby. Inmunology. 7a ed. México, DF: McGraw-Hill. Interamericana Editores, SA; 2013.

  26. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell Ipswich EE. Interleukin-10 Promoter Polymorphism Predicts Initial Response of Chronic Hepatitis C to Interferon Alfa. Hepatol. 1999;30:526-30. DOI: 10.1186/1743-422X-8-28

  27. Salhi ARJV, Santoro F, Dessein H, Romano A, Castellano LR. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol. 2008;180:6139-48. DOI: 10.4049/jimmunol.180.9.6139

  28. Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation. 2003;75(5):711-7. DOI: 10.1097/01.tp.0000055216.19866.9a

  29. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatol. 2014;59(1):318-27. DOI: doi:10.1002/hep.26744 6




2020     |     www.medigraphic.com